KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Cash from Financing Activities: 2009-2025

Historic Cash from Financing Activities for Ionis Pharmaceuticals (IONS) over the last 16 years, with Sep 2025 value amounting to $81.2 million.

  • Ionis Pharmaceuticals' Cash from Financing Activities fell 83.63% to $81.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.5 million, marking a year-over-year decrease of 92.80%. This contributed to the annual value of $478.1 million for FY2024, which is 25.78% down from last year.
  • According to the latest figures from Q3 2025, Ionis Pharmaceuticals' Cash from Financing Activities is $81.2 million, which was up 6,413.07% from $1.2 million recorded in Q2 2025.
  • Over the past 5 years, Ionis Pharmaceuticals' Cash from Financing Activities peaked at $496.0 million during Q3 2024, and registered a low of -$62.5 million during Q4 2021.
  • In the last 3 years, Ionis Pharmaceuticals' Cash from Financing Activities had a median value of $23.6 million in 2024 and averaged $109.7 million.
  • Within the past 5 years, the most significant YoY rise in Ionis Pharmaceuticals' Cash from Financing Activities was 11,713.83% (2023), while the steepest drop was 1,859.38% (2023).
  • Quarterly analysis of 5 years shows Ionis Pharmaceuticals' Cash from Financing Activities stood at -$62.5 million in 2021, then rose by 18.36% to -$51.0 million in 2022, then skyrocketed by 179.82% to $40.7 million in 2023, then plummeted by 208.33% to -$44.1 million in 2024, then slumped by 83.63% to $81.2 million in 2025.
  • Its last three reported values are $81.2 million in Q3 2025, $1.2 million for Q2 2025, and $2.2 million during Q1 2025.